International Journal of Clinical Research

Objective: To observe the effect of methotrexate + adalimumab in the treatment of early rheumatoid arthritis. Methods: 60 cases of early rheumatoid arthritis were collected and studied from January 2022 to December 2022. Methotrexate group (30 patients): methotrexate treatment alone. Methotrexate + adalimumab group (30 patients): the patients were treated with methotrexate + adalimumab. research effect. Results: Higher clinical efficacy in methotrexate + adalimumab group [96.67% (29 / 30), compared with 86.67% (23 / 30) with methotrexate group] (p <0.05). CRP levels were lower after 12 months with methotrexate + adalimumab [(8.59 ± 1.44) mg/L, mg/L (17.59 ± 2.36) in the methotrexate group] (p <0.05). After 12 months of treatment [(2.11 ± 0.45), (4.16 ± 1.03) in the methotrexate group] (p <0.05). The serum CD206 content was lower [(0.31 ± 0.02) mg/L, (0.24 ± 0.24 ± 0.02) mg/L, (0.22 ± 0.01) mg/L, compared with (0.34 ± 0.04) mg/L, (0.31 ± 0.13) mg/L, (0.29 ± 0.11) mg/L in the methotrexate group) (p <0.05). The incidence of adverse effects did not significantly increase in the methotrexate + adalimumab group [6.66% (2 / 30), compared with 13.33% (4 / 30) in the methotrexate group] (p> 0.05). Conclusion: Methotrexate + adalimumab is more effective in patients with early rheumatoid arthritis.

Early rheumatoid arthritis; methotrexate; adalimumab; curative effect